13F Holdings
中文EN

MGTX MeiraGTx Holdings plc

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1735438 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,365.9%
TTM net income YoY146.4%
TTM EPS YoY141.2%
Revenue 3-yr CAGR291.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin44.8%
Net margin19.5%
FCF margin-0.7%
EBITDA margin47.8%

Returns

ROE89.7%
ROA26.0%
ROIC (approx.)—
Asset turnover1.34x

Leverage & solvency

Liabilities / assets47.7%
Debt / equity0.00x
Current ratio4.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.02x
Accruals ratio25.6%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20212022-12-31FY20212021-12-31
Income statement
Revenue$81.39M$33.28M$14.02M$15.92M$37.70M
R&D expense$129.62M$119.48M$103.78M$85.72M$66.69M
SG&A expense$52.90M$54.22M$47.29M$46.55M$43.77M
Operating income-$105.97M-$164.21M-$137.06M-$116.36M-$72.76M
Interest expense$12.20M$13.27M$13.24M$4.95M$288,000
Pretax income-$114.20M-$147.79M-$84.03M-$129.62M-$79.56M
Income tax$0$0$0—$0
Net income-$114.20M-$147.79M-$84.03M-$129.62M-$79.56M
EBITDA-$93.43M-$151.38M-$123.33M-$107.63M-$64.89M
EPS (basic)-1.42-2.12-1.49-2.87-1.80
EPS (diluted)-1.42-2.12-1.49-2.87-1.80
Weighted avg. shares (diluted)80.43M69.82M56.49M45.18M44.14M
Balance sheet
Cash & equivalents$65.93M$105.67M$130.65M$115.52M$137.70M
Receivables$3.00M$707,000$10.14M$21.33M—
Inventory—$385,000———
Current assets$91.76M$123.52M$159.62M$154.34M$183.24M
PP&E, net$105.47M$102.88M$115.90M$109.27M$75.86M
Intangibles$578,000$821,000$1.12M$1.33M$1.79M
Total assets$244.43M$269.75M$326.74M$318.24M$320.16M
Current liabilities$122.56M$60.78M$67.08M$82.07M$68.13M
Total liabilities$250.22M$201.92M$188.57M$200.50M$134.76M
Shareholders' equity-$5.79M$67.83M$138.18M$117.74M$185.40M
Shares outstanding81.12M78.40M63.60M48.48M44.55M
Cash flow statement
Operating cash flow-$46.36M-$104.50M-$105.36M-$73.10M-$10.53M
Capital expenditure$3.83M$4.96M$20.17M$44.96M$46.35M
Free cash flow-$50.19M-$109.45M-$125.54M-$118.06M-$56.88M
Investing cash flow-$4.11M$23.48M$34.03M-$44.96M-$61.72M
Financing cash flow$12.27M$54.53M$84.02M$95.20M$1.71M
Depreciation & amortization$12.54M$12.83M$13.73M$8.72M$7.87M
Stock-based compensation$22.11M$25.19M$27.72M$28.62M$20.78M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.